



- (51) International Patent Classification:
A61K 39/09 (2006.01) *A61P 31/04* (2006.01)
- (21) International Application Number:
PCT/US2019/066682
- (22) International Filing Date:
17 December 2019 (17.12.2019)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/781,835 19 December 2018 (19.12.2018) US
62/853,331 28 May 2019 (28.05.2019) US
- (71) Applicant: **MERCK SHARP & DOHME CORP.**
[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).
- (72) Inventors; and
(71) Applicants (for US only): **ABEYGUNAWARDANA, Chitrananda** [US/US]; 351 North Summeytown Pike, North Wales, Pennsylvania 19454 (US). **CUI, Yadong Adam** [US/US]; 351 North Summeytown Pike, North Wales, Pennsylvania 19454 (US). **FERRERO, Romulo** [US/US]; 351 North Summeytown Pike, North Wales, Pennsylvania 19454 (US). **HE, Jian** [US/US]; 770 Summeytown Pike, West Point, Pennsylvania 19486 (US). **MUSEY, Luwy** [US/US]; 351 North Summeytown Pike, North Wales, Pennsylvania 19454 (US). **PETIGARA, Tanaz** [US/US]; 30 South 17th Street, Suite 1303, Philadelphia, Pennsylvania 19103 (US). **SKINNER, Julie, M.** [US/US]; 770 Summeytown Pike, West Point, Pennsylvania 19486 (US).
- (74) Common Representative: **MERCK SHARP & DOHME CORP.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(54) Title: COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: The invention is related to multivalent immunogenic compositions comprising more than one *S. pneumoniae* polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an *S. pneumoniae* serotype conjugated to a carrier protein, wherein the serotypes of *S. pneumoniae* are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against *S. pneumoniae* infection and/or pneumococcal diseases caused by *S. pneumoniae*. The compositions of the invention are also useful as part of treatment regimes

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

30 July 2020 (30.07.2020)

that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.